An Overview of the Field of Peptide and Protein Delivery

Peptide and Protein Delivery

Volumn , Issue , 2011, Pages 1-22

  van der Walle, Christopher F ^a   Olejnik, Orest ^b  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b ALLERGAN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882469329     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-384935-9.10001-X     Document Type: Chapter

References (52)

1. A.K. Pavlou and M.J. Belsey (2005) The therapeutic antibodies market to 2008. Eur. J. Pharm. Biopharm. 59 389-396.
2. J. Jones (2002) Amino Acid and Peptide Synthesis. Bath: The Bath Press
3. K. Sun-Chang, L.J. Hyun, K.M. Hyung, K.J. Hyun, H. Seung-Suh, L. Hyun-Soo, Method for mass production of antimicrobial peptide. Patent applicant: Samyang Genex Co. Ltd., Korea Advanced Inst Sci & Tech, Korea. Publication: WO9854336 (1998)–12–03.
4. T.E. Creighton (1993) Proteins: Structures and Molecular Properties. New York: W.H. Freeman
5. C.F. van der Walle, G. Sharma and M. Ravi Kumar (2009) Current approaches to stabilising and analysing proteins during microencapsulation in PLGA. Expert Opin. Drug Deliv. 6 177-186.
6. C. Black, E. Cummins, P. Royle, S. Philip and N. Waugh (2007) The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: A systematic review and economic evaluation. Health Technol. Assess. 11 1-126.
7. L.J. Harris, E. Skaletsky and A. McPherson (1998) Crystallographic structure of an intact IgG1 monoclonal antibody. J. Mol. Biol. 275 861-872.
8. U.S. Pharmacopeia. Particulate Matter in Injections In The United States Pharmacopeia –National Formulary, General Chapter <788>. (2010).
9. S.K. Singh, N. Rathore, A. McAuley and A.S. Rathore (2009) Best practices for formulation and manufacturing of biotech drug products: how to maintain product stability and prevent particulates. BioPharm Int. 22(6),
10. B.S. Kendrick, B.S. Chang, T. Arakawa, B. Peterson, T.W. Randolph, M.C. Manning, et al. (1997) Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc. Natl. Acad. Sci. U.S.A. 94 11917-11922.
11. Y. Jung, H.J. Kang, J.M. Lee, S.O. Jung, W.S. Yun, S.J. Chung, et al. (2008) Controlled antibody immobilization onto immunoanalytical platforms by synthetic peptide. Anal. Biochem. 374 99-105.
12. S.D. Allison, B. Chang, T.W. Randolph and J.F. Carpenter (1999) Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding. Arch. Biochem. Biophys. 365 289-298.
13. W. Wang (1999) Instability, stabilization, and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 185 129-188.
14. X. Tang and M.J. Pikal (2004) Design of freeze-drying processes for pharmaceuticals: Practical advice. Pharm. Res. 21 191-200.
15. S.L. Nail and J.A. Searles (2008) Elements of quality by design in development and scale-up of freeze-dried parenterals. BioPharm Int. 21(1),
16. H. Gieseler and G. Lee (2008) Effect of freeze-dryer design on drying rate of an amorphous protein-formulation determined with a gravimetric technique. Pharm. Dev. Technol. 13 463-472.
17. J.F. Carpenter, M.J. Pikal, B.S. Chang and T.W. Randolph (1997) Rational design of stable lyophilized protein formulations: Some practical advice. Pharm. Res. 14 969-975.
18. L.Q. Chang and M.J. Pikal (2009) Mechanisms of protein stabilization in the solid state. J. Pharm. Sci. 98 2886-2908.
19. M.V.S. Varma, S. Khandavilli, Y. Ashokraj, A. Jain, A. Dhanikula, A. Sood, et al. (2004) Biopharmaceutic classification system: A scientific framework for pharmacokinetic optimization in drug research. Curr. Drug Metab. 5 375-388.
20. J.L. Italia, V. Bhardwaj and M.N. Kumar (2006) Disease, destination, dose and delivery aspects of ciclosporin: The state of the art. Drug Discov. Today 11 846-854.
21. H. Liu, Y. Wang and S. Li (2007) Advanced delivery of ciclosporin A: Present state and perspective. Expert Opin. Drug Deliv. 4 349-358.
22. R.I. Henkin (2010) Inhaled insulin-intrapulmonary, intranasal, and other routes of administration: Mechanisms of action. Nutrition 26 33-39.
23. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus. ClinicalTrials.gov Identifier: NCT00419562, ClinicalTrials.gov. (2007).
24. F. Cui, K. Shi, L. Zhang, A. Tao and Y. Kawashima (2006) Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: Preparation, in vitro characterization and in vivo evaluation. J. Control. Release 114 242-250.
25. C. Damge, P. Maincent and N. Ubrich (2007) Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117 163-170.
26. B. Sarmento, A. Ribeiro, F. Veiga, D. Ferreira and R. Neufeld (2007) Oral bioavailability of insulin contained in polysaccharide nanoparticles. Biomacromolecules 8 3054-3060.
27. G. Sharma, K. Wilson, C.F. van der Walle, N. Sattar, J.R. Petrie and M.N. Ravi Kumar (2010) Microemulsions for oral delivery of insulin: Design, development and evaluation in streptozotocin induced diabetic rats. Eur. J. Pharm. Biopharm. 76 159-169.
28. L.H. du Plessis, A.F. Kotze and H.E. Junginger (2010) Nasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride. Drug Deliv. 17 399-407.
29. J. Guevara-Aguirre, M. Guevara-Aguirre, J. Saavedra, G. Bernstein and A.L. Rosenbloom (2007) Comparison of oral insulin spray and subcutaneous regular insulin at mealtime in type 1 diabetes. Diabetes Technol. Ther. 9 372-376.
30. F. Mohamed and C.F. van der Walle (2008) Engineering biodegradable polyester particles with specific drug targeting and drug release properties. J. Pharm. Sci. 97 71-87.
31. S. Hermeling, D.J.A. Crommelin, H. Schellekens and W. Jiskoot (2004) Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21 897-903.
32. F. Jordan, A. Naylor, C.A. Kelly, S.M. Howdle, A. Lewis and L. Illum (2010) Sustained release hGH microsphere formulation produced by a novel supercritical fluid technology: In vivo studies. J. Control. Release 141 153-160.
33. U. Puapermpoonsiri, J. Spencer and C.F. van der Walle (2009) A freeze-dried formulation of bacteriophage encapsulated in biodegradable microspheres. Eur. J. Pharm. Biopharm. 72 26-33.
34. P. Carter, L. Presta, C.M. Gorman, J.B. Ridgway, D. Henner, W.L. Wong, et al. (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 89 4285-4289.
35. H. Neumann, K. Wang, L. Davis, M. Garcia-Alai and J.W. Chin (2010) Encoding multiple unnatural amino acids via evolution of a quadruplet-decoding ribosome. Nature 464 441-444.
36. B.D. Moore, J. Deere, R. Edrada-Ebel, A. Ingram and C.F. van der Walle (2010) Isolation of recombinant proteins from culture broth by co-precipitation with an amino acid carrier to form stable dry powders. Biotechnol. Bioeng. 106 764-773.
37. J.A. Cavagnaro (2002) Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Nat. Rev. Drug Discov. 1 469-475.
38. G. Suntharalingam, M.R. Perry, S. Ward, S.J. Brett, A. Castello-Cortes, M.D. Brunner, et al. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 1018-1028.
39. D. Eastwood, L. Findlay, S. Poole, C. Bird, M. Wadhwa, M. Moore, et al. (2010) Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br. J. Pharmacol. 161 512-526.
40. F.J. Erbguth and M. Naumann (1999) Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology 53 1850-1853.
41. K.R. Aoki (2005) Pharmacology and immunology of botulinum neurotoxins. Int. Ophthalmol. Clin. 45 25-37.
42. E. Koren, L.A. Zuckerman and A.R. Mire-Sluis (2002) Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3 349-360.
43. P.J. Bugelski and G. Treacy (2004) Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr. Opin. Mol. Ther. 6 10-16.
44. S.K. Branch (2005) Guidelines from the International Conference on Harmonization (ICH). J. Pharm. Biomed. Anal. 38 798-805.
45. World Health Organization. The Impact of Implementation of ICH Guidelines in Non-ICH Countries – Regulatory Support Series No. 9, (2002), pp. 1–30.
46. M.A. Voet (2008) The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-cycle Management. 2nd ed. Boca Raton, USA: BrownWalker Press
47. B.-L. Chen (2009) CMC issues and regulatory requirements for biosimilars. Trends in Bio/Pharmaceutical Industry 5 19-26.
48. H. Schellekens and W. Jiskoot (2006) Eprex-associated pure red cell aplasia and leachates. Nat. Biotechnol. 24 613-614.
49. B. Sharma, M.H. Ryan and K. Boven (2006) Reactions to Eprex's adverse events. Nat. Biotechnol. 24 1199-1200.
50. A. Brashear (2008) Clinical comparisons of botulinum neurotoxin formulations. Neurologist 14 289-298.
51. A.S. Rathore and H. Winkle (2009) Quality by design for biopharmaceuticals. Nat. Biotechnol. 27 26-34.
52. R.B. Shah, J.T. Park, E.K. Read, M.A. Khan and K. Brorson (2010) Quality by design (QbD), biopharmaceutical manufacture. M.C. Flickinger (Ed.) Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology Oxford, UK: Wiley-Blackwell 1-36.